Cargando…
Toward Newborn Screening of Cerebrotendinous Xanthomatosis: Results of a Biomarker Research Study Using 32,000 Newborn Dried Blood Spots
PURPOSE: Cerebrotendinous xanthomatosis (CTX) is a treatable hereditary disorder caused by the deficiency of sterol 27- hydroxylase, which is encoded by the CYP27A1 gene. Different newborn screening biomarkers for CTX have been described, including 7α,12α-dihydroxy-4-cholesten-3-one ( 7α12αC4 ), 5b-...
Autores principales: | Hong, Xinying, Daiker, Jessica, Sadilek, Martin, DeBarber, Andrea E., Chiang, John, Duan, Jie, Bootsma, Albert H., Huidekoper, Hidde H., Vaz, Frédéric M., Gelb, Michael H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529987/ https://www.ncbi.nlm.nih.gov/pubmed/32523054 http://dx.doi.org/10.1038/s41436-020-0846-x |
Ejemplares similares
-
Newborn screening for Cerebrotendinous Xanthomatosis: A retrospective biomarker study using both flow-injection and UPLC-MS/MS analysis in 20,000 newborns
por: Vaz, Frédéric M., et al.
Publicado: (2023) -
Update on newborn dried bloodspot testing for cerebrotendinous xanthomatosis: An available high-throughput liquid-chromatography tandem mass spectrometry method
por: Bleyle, Lisa, et al.
Publicado: (2016) -
Quality scores for 32,000 genomes
por: Land, Miriam L, et al.
Publicado: (2014) -
Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment
por: Huidekoper, Hidde H., et al.
Publicado: (2015) -
Familial variability of cerebrotendinous xanthomatosis lacking typical biochemical findings
por: Guenzel, Adam J., et al.
Publicado: (2021)